Abionyx Pharma SA Logo

Abionyx Pharma SA (ABNX)

Euronext

Currency in EUR
1.62
-0.09 (-5.04%)

Closed

Oct 2, 2026

Day's Range

1.61
1.67

52 wk Range

1.61
5.29

Overview - ABNX - Abionyx Pharma SA

Key Statistics

Valuation

Enterprise Value

65.22M

P/E (Trailing)

‪-10.43‬

P/E (Forward)

‪-6.08‬

PEG Ratio

‪-6.08‬

Price / Sales (TTM)

‪18.31‬

Price / Book

‪13.35‬

EV / EBITDA

‪-12.02‬

Profitability

Profit Margin

‪-136.59%‬

Operating Margin

‪-165.02%‬

Return on Assets

‪-25.97%‬

Return on Equity

‪-92.29%‬

Ownership

Shares Outstanding

35.83M

Float

22.33M

Held by Insiders

‪29.17%‬

Held by Institutions

‪3.63%‬

Price stats

Beta

‪0.45‬

50-Day Avg

‪1.92‬

200-Day Avg

‪3.00‬

Dividends

Payout Ratio

‪0.00%‬

Analyst Consensus

Buy

3 analysts

News Teaser - ABNX - Abionyx Pharma SA

News & Analysis

View all news

Market Cap - ABNX - Abionyx Pharma SA

Peers - ABNX - Abionyx Pharma SA

Peer Comparison

Compared with companies in Biotechnology listed on Euronext.

Profile Summary - ABNX - Abionyx Pharma SA

About

Abionyx Pharma SA is a new-generation biotechnology company focused on discovering and developing innovative therapies for patients lacking effective treatments, particularly in renal and ophthalmological diseases. It specializes in HDL (High Density Lipoprotein) therapies, leveraging advanced lipoprotein particles to…

SectorHealthcare
IndustryBiotechnology
Employees49
Full company profile

The information on this page is provided for general informational purposes only and is not investment advice.

Market data provided by Twelve Data. Charting by TradingView.

Last updated:

Track Global Markets in Real Time with UA Finance

Download the app now and access live financial data, expert analysis, and trusted economic news to follow stocks, forex, gold, and cryptocurrencies with ease.